Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
The Bank of New York Mellon Corporation (BNYMC) has increased its substantial holding in Alterity Therapeutics Limited, now holding a 27.03% voting power compared to the previous 26.01%. This change indicates a growing interest and confidence in Alterity’s operations, potentially impacting the company’s market positioning and stakeholder relations.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. The company is dedicated to creating innovative treatments that address unmet medical needs, particularly in the area of brain health.
YTD Price Performance: 10.0%
Average Trading Volume: 20,625,708
Technical Sentiment Signal: Sell
Current Market Cap: A$91.27M
Learn more about ATH stock on TipRanks’ Stock Analysis page.